Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Mattias Ohlsson

Mattias Ohlsson

Professor

Mattias Ohlsson

Technical advances of the recombinant antibody microarray technology platform for clinical immunoproteomics

Author

  • Payam Delfani
  • Linda Dexlin Mellby
  • Malin Nordström
  • Andreas Holmér
  • Mattias Ohlsson
  • Carl A K Borrebaeck
  • Christer Wingren

Summary, in English

In the quest for deciphering disease-associated biomarkers, high-performing tools for multiplexed protein expression profiling of crude clinical samples will be crucial. Affinity proteomics, mainly represented by antibody-based microarrays, have during recent years been established as a proteomic tool providing unique opportunities for parallelized protein expression profiling. But despite the progress, several main technical features and assay procedures remains to be (fully) resolved. Among these issues, the handling of protein microarray data, i.e. the biostatistics parts, is one of the key features to solve. In this study, we have therefore further optimized, validated, and standardized our in-house designed recombinant antibody microarray technology platform. To this end, we addressed the main remaining technical issues (e.g. antibody quality, array production, sample labelling, and selected assay conditions) and most importantly key biostatistics subjects (e.g. array data pre-processing and biomarker panel condensation). This represents one of the first antibody array studies in which these key biostatistics subjects have been studied in detail. Here, we thus present the next generation of the recombinant antibody microarray technology platform designed for clinical immunoproteomics.

Department/s

  • Department of Immunotechnology
  • Create Health
  • Computational Biology and Biological Physics
  • BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation

Publishing year

2016-07-01

Language

English

Publication/Series

PLoS ONE

Volume

11

Issue

7

Document type

Journal article

Publisher

Public Library of Science

Topic

  • Medical Biotechnology

Status

Published

ISBN/ISSN/Other

  • ISSN: 1932-6203